<DOC>
	<DOCNO>NCT02265393</DOCNO>
	<brief_summary>This 2-part study OTO-104 subject unilateral Meniere 's disease United Kingdom . The first part randomize , placebo-controlled study compare safety profile 2 injection OTO-104 placebo space 3 month apart . The second part open-label extension subject receive additional 2 intratympanic injection OTO-104 space 3 month apart . Each subject participate study total 1 year .</brief_summary>
	<brief_title>A 1-Year Safety Study OTO-104 Subjects With Unilateral Meniere 's Disease Located United Kingdom</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria include , limited : Subject diagnosis definite unilateral Meniere 's disease . Subject agree maintain current standard care treatment Meniere 's disease onstudy . Exclusion Criteria include , limited : Subject pregnant lactating . Subject history immunodeficiency disease . Subject history previous endolymphatic sac surgery . Subject history previous use intratympanic gentamicin affect ear . Subject history drop attack . Subject experience adverse reaction intratympanic injection steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>